Apologies in advance for the long post... click Next if you

New Post Public Reply Private Reply Replies (2) Message Board
Warp Daveludlow #6219
Apologies in advance for the long post... click Next if you don't want to waste the next 2 minutes of your life. LOL

Dave, the dilution concern you continue to refer to as legitimate is obviously not shared by the majority on this board. We are not the naive investors as you think we are. But your concerns over this issue are starting to sound like the rants of those who believe the moon landings were faked, and are frustrated they can't convince everyone else of the truth of this. Seriously, you need to get a grip. Take your concerns to the company, or sell your shares. Most of the naive investors here understand the dilution concern yet we choose to remain invested and keep our focus on the company and the bright outlook of our future.

So your 1.1 million shares represent hard earned money, do they? What the hell do my shares represent? You have no f*cking idea what you're talking about when you make any attempt to characterize me or my investment style. I take my concerns to the source, not to a public message board where others can do little to nothing about it. Gerald has personally addressed every one of my concerns, and in some cases stated the company would be addressing those concerns in the near future, which they have. I'm satisfied with that. If that's a passive investor, then I suppose I choose to remain a passive investor vs. claiming to be a LT investor yet fretting and losing sleep over every possible outcome in my investment. I feel management has enough challenges ahead of them without me creating more by constantly reminding them of my own insecurities with my investment decision. As Gerald has stated, they are building a world-class biotech company, and if I can't stand the heat of the kitchen, then I should sell my shares and move on. Good advice, in my opinion.

It is not the CEO's job to manage my investment as you claim. It is management's job to manage the company and bring shareholder value, using their knowledge and experience to manage the science and build the best shareholder value they can based on bringing their assets to market. It is my job to manage my investment. It is my job to decide to stick with this investment or not based on my results and how I view the company being managed. It is not my job to try to manage the company, nor attempt to sway investor sentiment to agree with my opinion and put pressure on management to better manage my investment. They are busy running the company. If I had the qualifications to manage the company, I'd be working for them, not simply buying their shares.

You seem to believe I'm wealthy. Again, your analysis here sucks. What is your definition of wealth? And how do you think I came into the money to buy my large position? I'll tell you how. I worked my ass off for years, working 12-hour rotating shifts, and adding 600+ hours annually of overtime for many years. While others were taking off to spend time with family and friends on weekends and holidays, I was at the nuclear plant working. So I would characterize my investment dollars just as hard earned, if not more so, than those you've put into your investment. So how about less talk of your hard-earned dollars? Most here earned the money they invest. Your dollars are no different than anyone else's here.

I can assure you of this... if I only owned 100K or 500K in AMBS shares, my concern over possible dilution ahead would be no different than it is now. I live in reality, not the fantasy world you suggest. The real world would have investors who wouldn't invest in pre-revenue biotech companies if they were concerned about dilution. In the fantasy world, investors invest in such companies often to counter their life-long tendency to borrow for everything, not save enough for retirement, and pin all of their hopes on striking it rich, which is why they fret over everything that "might" happen with their investment, instead of having more trust in management to do what is best both for shareholders and the company.

Let me tell you how I view God in this environment. I pray for Gerald and his team, and those conducting the research to help those in need. I pray that this investment will work out the way God intends, whatever that may be. And I pray God has my best interests in mind, whether that is to provide me with abundant wealth to help others in need, or to teach me a valuable lesson about what many would consider my foolish investment of my limited resources in a risky company like Amarantus.

So, while you are fretting and flipping out over what might happen, I have faith this will all work out as God intended. Gerald is not God. But I believe he is genuinely a good person and may very well be one of God's instruments to help those suffering from these various afflictions. And if I'm blessed to enjoy some rewards as a shareholder, I will certainly do my part in passing on some of those blessings to others in need, as well as my local church to spread God's ministry. If you think that's a "passive" investor, so be it. I imagine my blood pressure and sleep patterns are a lot better than yours. And my faith this will all work according to God's plan gives me comfort. That doesn't mean I don't bring my concerns to the company. One would be a fool to blindly invest and hope it all works out, but we obviously have different levels of faith in this investment.

I'd rather drink Kool-Aid than whatever brew you're drinking. What I'm drinking isn't causing unnecessary concerns over what might happen down the road. You really should watch a specific episode of Deep Space Nine called "Statistical Probabilities" (season 6, episode 9). It is a prime example of your over-analysis of everything Amarantus, and how a single event can change everything and make all of the analysis moot.

Speaking of maturity, it seems to me most here are calm adults who understand the risks. But some seem to be spoiled brats crying for attention and pissed off that everyone else doesn't share their concerns.

One final point... you should work on your reading skills because your mention of my post regarding one of the callers on the recent business update call is way off.

What you posted:
Quote:
Unlike Warp, I thought the gentleman who pressed Gerald on those 5 questions during the CC was right on!! Warp writes off discussion about concerns as anxious "hand wringing" and the cause of "sleepless nights" that only the poor engage in, who really shouldn't be invested in this type of stock in the first place. I thought the gentleman asking the questions on the CC was respectful, but earnest.
What I posted:
Quote:
I sat here listening to these 5 questions and was scratching my head, particularly the ones asking Gerald to reveal any partnerships or asset sales in the works, and when the company expected to be profitable. It's sad this investor took up so much time on the call where other investors could have asked reasonable questions that Gerald might be able to legally answer.

So you believe a reasonable investor question would be for specifics on upcoming sales of the LymPro and Eltoprazine assets, or when the company will reach profitability based on partnership agreements or asset sales currently in the works? You really see those questions as respectful and ernest? What fantasy world are you living in? There's no way Gerald could answer those questions, and not wind up with SEC fines or removal by the BOD as CEO. Respectful and ernest? What kind of shareholder would even ask those questions? One who is out of his league as an investor here and should stick with investing in mutual funds. I'm surprised you feel these were valid questions that should be asked.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sarepta Under Scrutiny: KSF's Investigation Deepens

Updated Category News Views 3

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Continue Reading
Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Updated Category News Views 4

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 3

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
Postal Service Defends New Rule Amid Speculation

Updated Category News Views 3

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Continue Reading
Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 6

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
TrailBlazer Magazine Snags a Tribune for In-House Design

Updated Category News Views 4

Who Knew? Design Awards Aren't Just for Pretty Pictures TrailBlazer Magazine gets a pat on the back from GDUSA's 2026 Inhouse Design Awards, a nod to top-notch design work. With over 4,000 entries across the board, getting into the top 10 percent is like finding a steakhouse with zero line on a Friday night. Not exactly common, right? Design Worth Cheering For The winning...

Continue Reading
MMRO Achieves URAC AI Accreditation, Ensures Compliance

Updated Category News Views 4

A Milestone in Healthcare AI: MMRO's New Accreditation When AI in healthcare gets an official nod from the big guys like URAC, it's a significant moment. We're talking about Managed Medical Review Organization, Inc. (MMRO), a firm that's just earned the URAC Artificial Intelligence in Health Care Accreditation. Now, this isn't just some rubber stamp; it's a testament to...

Continue Reading
Dimerix Locks Down A$34M Loan: No Shareholder Dilution

Updated Category News Views 2

Dimerix Grabs Non-Dilutive Funds amid Kidney Trials Here we go with Dimerix's latest move, folks. They roped in A$34 million through a cozy get-together with lenders from Australia and the U.S. What's the kicker? This cash won't touch shareholder equity. So, breathe easy, investors. It's a rare feat to pull off non-dilutive funds these days, especially in the biopharma...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming the Narcolepsy Market: Innovations Ahead

Updated Category News Views 166

The Evolving Landscape of the Narcolepsy Market The narcolepsy market is undergoing significant changes as it shifts from merely managing symptoms to developing targeted therapies that tackle the root causes of the disorder. Traditionally, treatments focused on alleviating symptoms, but advancements now emphasize addressing the underlying neurochemical issues, primarily...

Continue Reading
UBS Analysts Share Insights on China Stocks Strategies

Updated Category News Views 242

UBS Analysts Offer Insights on China's Equity Market In a recent discussion, UBS strategists have expressed a level of caution regarding China's equity market as they look into the evolving landscape of 2025. It's noted that local A-share investors appear hesitant to seize buying opportunities, influenced by a myriad of factors that create uncertainty in the market....

Continue Reading
Palisade Bio's Special Meeting Cancellation: What You Need to Know

Updated Category News Views 133

Palisade Bio Cancels Special Meeting of Stockholders Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company making strides in developing innovative treatments for autoimmune, inflammatory, and fibrotic diseases. Recently, the company announced an important decision regarding its special meeting of stockholders. The special meeting, originally...

Continue Reading
Vivendi Reports Impressive 4.5% Revenue Growth in 2024

Updated Category News Views 123

Remarkable Revenue Growth for Vivendi Vivendi has announced an impressive increase in its revenues for the first nine months of 2024, emphasizing strong growth across its core business sectors. The company reported a revenue increase of 4.5% at constant currency and perimeter, compared to the same period in the previous year. This growth showcases the resilience and...

Continue Reading
Revolution in Home Renovation Arrives with Spray-Net Franchise

Updated Category News Views 226

Fresh Approach to Home Makeovers Home remodeling isn’t just about slapping on a new coat of paint anymore. In February 2026, Spray-Net is gearing up to launch in Allen, Texas, shaking things up in the renovation game. This venture represents a leap forward—not only for franchise growth but for homeowners who are sick and tired of traditional, drawn-out renovations....

Continue Reading